Gestational Response, Outcomes, and Weight After GLP-1 Use

NCT07743567 | Recruiting

• 1 other identifier: STUDY00162395
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes. The main aims of the study are to:

• Compare gestational weight gain between women with preconception GLP-1RA exposure and those without exposure.
• Compare obstetrical outcomes between women with preconception GLP-1RA exposure and those without exposure. Researchers will compare pregnant women with a history of GLP-1RA use to pregnant women who have not used a GLP-1RA to compare differences. Participants will be asked to complete questionnaires at multiple timepoints during and after pregnancy that ask questions about medication history, thoughts and feelings around food, etc.

Conditions

Pregnant Individuals; Obesity & Overweight; Gestational Weight Gain

Keywords

Glucagon-like peptide 1 receptor agonist; Pregnancy; Gestational weight gain; Maternal obesity; Pregnancy outcomes; Food noise; Preconception

Outcome Measures

Primary Outcomes (1)

• Gestational weight gain

  Total gestational weight gain, calculated from clinical weight measurements recorded in the electronic medical record and compared between participants with preconception GLP-1RA exposure and those without exposure.

  From the start of pregnancy to delivery.

Study Arms (2)

GLP-1RA users

Participants with a history of GLP-1RA use.

GLP-1RA nonusers

Participants who have never used a GLP-1RA medication.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pregnant women being seen at The University of Kansas Health System for an initial prenatal visit.

You may qualify if:

• Adult women
• Less than or equal to 20 weeks gestation at first visit
• English speaking

You may not qualify if:

• \<18 years at time of initial visit
• Type 2 diabetes
• History of bariatric surgery
• Multiple gestation
• Cannot consent for themselves
• Cannot read and speak English
• Incarcerated

Sponsors & Collaborators

• University of Kansas Medical Center: lead

Study Sites (1)

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

RECRUITING

Related Publications (2)

• Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes. JAMA Netw Open. 2024 May 1;7(5):e2413172. doi: 10.1001/jamanetworkopen.2024.13172.

  PMID: 38787563 BACKGROUND

• Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, Soria-Contreras DC, Shook LL, Mow C, Hivert MF, Thaweethai T, Powe CE. Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA. 2025 Dec 23;334(24):2186-2196. doi: 10.1001/jama.2025.20951.

  PMID: 41284263 BACKGROUND

MeSH Terms

Conditions

Obesity; Overweight; Gestational Weight Gain; Pregnancy in Obesity

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Weight Gain; Body Weight Changes; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Central Study Contacts

Molly Fain

CONTACT

913-588-5478; mfain3@kumc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Assistant Professor

Study Record Dates

• First Submitted: July 30, 2026
• First Posted: August 4, 2026
• Study Start: April 13, 2026
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2028
• Last Updated: August 4, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)